UNC Center for AIDS Research

It's about a real-life response to AIDS - a fierce commitment to creating and translating knowledge that advances the fight against HIV & AIDS

Acknowledge the CFAR Request A Service
  • About
    • Center Overview
    • Resources
      • HIV Matters Podcast Series
      • Training Tools
      • Related Organizations & Websites
    • Acknowledge the CFAR
    • Contact Us
  • Cores & Services
    • Administrative
      • CFAR Office of Community Engagement (OCE)
    • Biostatistics
    • Clinical
    • Clinical Pharmacology/Analytical Chemistry
    • Developmental
    • HIV/STD Laboratory (formerly VIM)
    • International
    • Social & Behavioral Science
  • Working Groups
  • Membership
  • News & Events
    • CFAR News & Announcements
    • CFAR Newsletters
    • Events Calendar
    • Friday Morning Conference
    • CFAR-Wide Webinar Series
    • 2019 Scientific Symposium
    • 2019 NCCC Community Symposium

‘Landmark’ study finds long-acting injectable drug highly effective in preventing HIV

May 19, 2020

Results from HPTN 083, a global large-scale study, show that the long-acting drug cabotegravir (CAB LA) is highly effective for prevention of HIV acquisition in cisgender men and transgender women. The study compares effectiveness of injections and oral tablets as pre-exposure prophylaxis (PrEP) and is the first large-scale clinical trial of a long-acting injectable drug for HIV prevention.

“The decades-long search for a vaccine to prevent HIV reached a new milestone as results from HPTN 083, a global large-scale study, show that the long-acting drug cabotegravir (CAB LA) protects uninfected people from HIV. The study, begun in December 2016, compared the safety and efficacy of the injectable drug, given every two months, to Truvada, a daily pill combining two drugs, for pre-exposure prophylaxis, or PrEP. Findings showed that CAB LA lowered HIV incidence among cisgender men and transgender women who have sex with men, leading to a promising alternative to daily medication.”

This story first appeared May 18, 2020 on the UNC Institute for Global Health and Infectious Diseases website.

News

Recent Posts

  • NICHD Grant Award Enables Researchers To Address Reasons For Vertical Transmission of HIV in Malawi As the Country Pursues Elimination Goals: Integrated Educational Cores Represent the Best of Capacity Building with Malawian Health Leaders
  • Gut Microbiome Can Increase Risk, Severity of HIV, EBV Disease
  • UNC CFAR Biostatistics Core Director, Michael Hudgens appointed to lead Gillings School’s Department of Biostatistics
  • UNC CFAR’s HIV/STD Core Associate Director, De Paris Receives Grant to Study HIV Vaccination in Infant Disease Models
  • Highlights from the 2023 HPTN Annual Meeting

GET IN TOUCH

UNC Center for AIDS Research
Lineberger Cancer Center
Chapel Hill, NC 27599
Email: prema_menezes@med.unc.edu

Follow Us

CFAR User Login
small_blue_trans
© 2018-2023 UNC CFAR. All rights reserved. Website by AndiSites Inc.